Concepedia

Author

Nikoletta Lendvai

Memorial Sloan Kettering Cancer Center

Also Known As

N Lendvai, N. Lendvai, Nikoletta K. Lendvai, Nikoletta Lendvai

217

Publications

5.2K

Citations

35

H-Index

58

Concepts

All Affiliations

Memorial Sloan Kettering Cancer CenterCornell UniversityJanssen (United States)Dana-Farber Cancer InstituteMedical College of Wisconsin
NL

About

Nikoletta Lendvai is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

19

1.6K

2

Immunology

9

9

529

3

Health Sciences

8

8

287

4

Cell Biology

5

5

184

5

Biochemistry

1

1

72

Nikoletta Lendvai

×

61

Publications

4.6K

Citations

34

H-Index

YearCitations

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros,

The Lancet Oncology

2019

772

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong,

New England Journal of Medicine

2023

615

Characterization of a Murine Monoclonal Antibody to<i>Cryptococcus neoformans</i>Polysaccharide That Is a Candidate for Human Therapeutic Studies

Arturo Casadevall, Wendy Cleare, Marta Feldmesser,

Antimicrobial Agents and Chemotherapy

1998

303

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat,

The Lancet Oncology

2018

235

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Adam D. Cohen, Samir Parekh, Bianca Santomasso,

Blood Cancer Journal

2022

235

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat,

Blood Cancer Journal

2019

210

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes <i>SDHA</i>, <i>TMEM127</i>, <i>MAX</i>, and <i>SDHAF2</i> for Gene-Informed Prevention

Birke Bausch, Francesca Schiavi, Ying Ni,

JAMA Oncology

2017

194

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Thomas G. Martin, Rachid Baz, Don M. Benson,

Blood

2017

163

Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice

Artur Jurczyszyn, Norbert Grząśko, Alessandro Gozzetti,

American Journal of Hematology

2016

132

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Sham Mailankody, Arnab Ghosh, Terence J. Purdon,

Blood

2018

99

Page 1